{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:10:13Z","timestamp":1772993413834,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40261-018-0624-6","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T07:01:19Z","timestamp":1518418879000},"page":"389-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies"],"prefix":"10.1007","volume":"38","author":[{"given":"Vinicius Lins","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia Paula","family":"Leonart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Stumpf","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Hiemisch Lobo","family":"Borba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"624_CR1","unstructured":"World Health Organization (WHO). Hepatitis C fact sheet no. 164 (updated July 2017). http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed 10 Aug 2017."},{"key":"624_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","volume":"55","author":"EASL","year":"2011","unstructured":"EASL. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245\u201364.","journal-title":"J Hepatol."},{"key":"624_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","volume":"8","author":"MS Sulkowski","year":"2011","unstructured":"Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212\u201323.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"624_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"EASL","year":"2015","unstructured":"EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199\u2013236.","journal-title":"J Hepatol."},{"key":"624_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"American Association for the Study of Liver Diseases","year":"2015","unstructured":"American Association for the Study of Liver Diseases. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932\u201354.","journal-title":"Hepatology."},{"key":"624_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40261-017-0565-5","volume":"37","author":"H Ahmed","year":"2017","unstructured":"Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA, et al. Safety and efficacy of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig. 2017;37:1009\u201323.","journal-title":"Clin Drug Investig."},{"key":"624_CR7","volume-title":"Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Updated version, 2016","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Updated version, 2016. Geneva: World Health Organization; 2016."},{"issue":"7","key":"624_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40261-017-0521-4","volume":"37","author":"VL Ferreira","year":"2017","unstructured":"Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials. Clin Drug Investig. 2017;37(7):635\u201346.","journal-title":"Clin Drug Investig."},{"issue":"4","key":"624_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/jgh.13620","volume":"32","author":"VL Ferreira","year":"2017","unstructured":"Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Muzzillo DA, et al. Ledipasvir\/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. J Gastroenterol Hepatol. 2017;32(4):749\u201355.","journal-title":"J Gastroenterol Hepatol."},{"issue":"5","key":"624_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/jcpt.12426","volume":"41","author":"VL Ferreira","year":"2016","unstructured":"Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther. 2016;41(5):478\u201385.","journal-title":"J Clin Pharm Ther."},{"key":"624_CR11","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1590\/1516-3180.2014.1321784","volume":"132","author":"AW Mariani","year":"2014","unstructured":"Mariani AW, Pego-Fernandes PM. Observational studies: why are they so important? Sao Paulo Med J. 2014;132:01\u20132.","journal-title":"Sao Paulo Med J."},{"key":"624_CR12","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.clinthera.2007.07.004","volume":"29","author":"RJ Ligthelm","year":"2007","unstructured":"Ligthelm RJ, Borz\u00ec V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29:1284\u201392.","journal-title":"Clin Ther."},{"key":"624_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2046-4053-3-35","volume":"3","author":"M O\u2019Neil","year":"2014","unstructured":"O\u2019Neil M, Berkman N, Hartling L, Chang S, Anderson J, Motu\u2019apuaka M, et al. Observational evidence and strength of evidence domains: case examples. Syst Rev. 2014;3:35.","journal-title":"Syst Rev."},{"key":"624_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/jrsm.1078","volume":"4","author":"HJ Sch\u00fcnemann","year":"2013","unstructured":"Sch\u00fcnemann HJ, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Res Synth Methods. 2013;4:49\u201362.","journal-title":"Res Synth Methods."},{"key":"624_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/POR.S137701","volume":"8","author":"MS Barnish","year":"2017","unstructured":"Barnish MS, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res. 2017;8:49\u201355.","journal-title":"Pragmat Obs Res."},{"key":"624_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1592\/phco.30.10.973","volume":"30","author":"NA DiPietro","year":"2010","unstructured":"DiPietro NA. Methods in epidemiology: observational study designs. Pharmacotherapy. 2010;30:973\u201384.","journal-title":"Pharmacotherapy."},{"key":"624_CR17","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ."},{"key":"624_CR18","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Copenhagen: Cochrane Collaboration; 2011."},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008\u201312.","journal-title":"JAMA."},{"key":"624_CR20","doi-asserted-by":"publisher","first-page":"e59202","DOI":"10.1371\/journal.pone.0059202","volume":"8","author":"RM Turner","year":"2013","unstructured":"Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One. 2013;8:e59202.","journal-title":"PLoS One."},{"key":"624_CR21","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"GA Wells","year":"2013","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2013."},{"key":"624_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/HMER.S113681","volume":"9","author":"A Gomaa","year":"2017","unstructured":"Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med. 2017;9:17\u201325.","journal-title":"Hepat Med."},{"key":"624_CR23","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med."},{"key":"624_CR24","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med."},{"key":"624_CR25","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608\u201317.","journal-title":"N Engl J Med."},{"key":"624_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Br\u00e4u N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448\u201355.","journal-title":"N Engl J Med."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-018-0624-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0624-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0624-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:20:27Z","timestamp":1659104427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-018-0624-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0624-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"12 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vinicius Lins Ferreira, Let\u00edcia Paula Leonart, Fernanda Stumpf Tonin, Helena Hiemisch Lobo Borba, and Roberto Pontarolo declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}